Sold out
Interested in Wholesale?
Contact Us Now
Be The First To Know About Wholesale, Exclusive Sales & More
Wegovy Korean Version
Wegovy® (semaglutide), an GLP-1 receptor agonist, treats obesity (BMI≥30) or overweight (BMI≥27) with comorbidities like hypertension. In 68-week trials, patients achieved 15% mean weight loss (35 lb from 232 lb baseline), with 86% losing ≥5% and 30% ≥20%. Regulates hypothalamic appetite signals and delays gastric emptying for sustained effects. Features a 5-step dose escalation protocol (20 weeks) to minimize GI intolerance, while improving BP, lipids, and HbA1c for long-term weight maintenance.
$448.00
Wegovy® (semaglutide) Injection
Wegovy® is an GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. Clinical trials demonstrate 15% mean body weight reduction (35 lb from 232 lb baseline) over 68 weeks, with 86% achieving ≥5% weight loss. Combines appetite regulation through hypothalamic signaling and delayed gastric emptying for sustained caloric deficit when used with lifestyle interventions.
Clinically Proven Efficacy
3X greater weight loss vs placebo (68-week phase III study, N=1,961)
Dose-Titration Protocol
5-step escalation over 20 weeks minimizes GI intolerance
Multi-System Benefits
Improves cardiometabolic markers (BP, LDL-C, HbA1c)
Long-Term Maintenance
2-year extension shows sustained 15% weight control
Mechanism of Action
Packaging & Dosage
Storage: Refrigerate at 2–8°C. Do not freeze.
Administration: Single-use prefilled pen. Discard after use.
Clinical Administration Protocol
Frequency
Once weekly, any time of day
Injection Sites
Abdomen, thigh, or upper arm
Dose Adjustment
Mandatory 4-week titration period
Important Safety Information
*Individual results may vary. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2. Monitor for pancreatitis and gallbladder events.
This product is available only through licensed healthcare providers. Novo Nordisk assumes no liability for unsupervised use.
| ProType |
0.25mg, 0.5mg, 1.7mg, 1mg, 2.4mg |
|---|
Related Products
INNO-TDS Face Nade Formula 4231
A face-specific contour formula for buyers who need a clearer story than a one-size-fits-all contour product. INNO-TDS Face Nade Formula 4231 combines six named actives in a professional 4 × 2.5 mL presentation, positioned around facial definition and firmer, more toned-looking skin.
- Dedicated facial-contour positioning
- Carnitine, Cynara, Melilotus, Tyrosine, Lecithin and Troxerutin
- Four 2.5 mL vials per box
A strong portfolio fit for clinics and distributors building a more concern-led facial contour range. Product selection and outcomes depend on professional assessment; follow the supplied label and local requirements.
Saxenda 3ml Liraglutide Injection Pen
Saxenda (liraglutide 3ml injection pen) is an prescription medication for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. Clinical trials demonstrate 56% of patients achieved ≥5% weight loss at 56 weeks when combined with lifestyle changes, with an average 8% body weight reduction. As a GLP-1 receptor agonist, it suppresses appetite by delaying gastric emptying by 31% and enhances satiety, while improving metabolic health markers like HbA1c (-0.6%) and systolic blood pressure (-2.8mmHg).
Interested in Wholesale?
Contact Us Now
Be The First To Know About Wholesale, Exclusive Sales & More
Reviews
Clear filtersThere are no reviews yet.